Citius Pharmaceuticals, Inc. SEC filings CTXR
Citius Pharmaceuticals, Inc. has 638 filings in SEC EDGAR's recent list, going back to Nov 23, 2010. Its latest annual report, Form ARS, was filed on Feb 24, 2026 for the period ended Sep 30, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (other events). The company's fiscal year ends on September 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-3 | Shelf registration | May 22, 2026 | — |
| 424B5 | Prospectus supplement | Apr 24, 2026 | — |
| 424B5 | Prospectus supplement | Oct 21, 2025 | — |
| 424B5 | Prospectus supplement | Jun 11, 2025 | — |
| 424B5 | Prospectus supplement | Apr 2, 2025 | — |
| 424B5 | Prospectus supplement | Jan 8, 2025 | — |
| 424B5 | Prospectus supplement | Nov 18, 2024 | — |
| 424B5 | Prospectus supplement | Aug 12, 2024 | — |
| 424B5 | Prospectus supplement | Apr 26, 2024 | — |
| S-3 | Shelf registration | Feb 23, 2024 | — |
| S-8 | Employee stock plan registration | Feb 23, 2024 | — |
| 424B5 | Prospectus supplement | May 5, 2023 | — |
| S-8 | Employee stock plan registration | Feb 10, 2023 | — |
| 424B4 | Prospectus | Jul 23, 2021 | — |
| POS AM | Post-effective amendment no. 2 to form s-1 | Jul 2, 2021 | — |
| S-8 | Employee stock plan registration | Jun 22, 2021 | — |
| 424B3 | Prospectus | May 20, 2021 | — |
| S-3 | Shelf registration | May 13, 2021 | — |
| 424B3 | Prospectus | Apr 16, 2021 | — |
| S-3 | Shelf registration | Apr 2, 2021 | — |
| 424B3 | Prospectus | Apr 1, 2021 | — |
| 424B3 | Prospectus | Mar 26, 2021 | — |
| 424B5 | Prospectus supplement | Feb 18, 2021 | — |
| S-3MEF | Registration statement | Feb 16, 2021 | — |
| 424B3 | Prospectus | Feb 5, 2021 | — |
| S-3 | Shelf registration | Jan 29, 2021 | — |
| POS AM | Post-effective amendment no. 1 to form s-3 | Sep 25, 2020 | — |
| 424B3 | Prospectus | Sep 25, 2020 | — |
| S-3 | Shelf registration | Sep 11, 2020 | — |
| 424B5 | Prospectus supplement | Aug 7, 2020 | — |
| FWP | Free writing prospectus | Aug 6, 2020 | — |
| FWP | Free writing prospectus | Aug 5, 2020 | — |
| 424B5 | Prospectus supplement | Aug 5, 2020 | — |
| 424B3 | Prospectus | Jun 12, 2020 | — |
| S-1 | Registration statement | Jun 5, 2020 | — |
| 424B5 | Prospectus supplement | May 15, 2020 | — |
| 424B3 | Prospectus | Apr 24, 2020 | — |
| S-1 | Registration statement | Apr 10, 2020 | — |
| 424B3 | Prospectus | Feb 18, 2020 | — |
| 424B3 | Prospectus | Feb 18, 2020 | — |
| S-8 | Employee stock plan registration | Dec 16, 2019 | — |
| 424B4 | Prospectus | Sep 26, 2019 | — |
| S-1/A | Amended registration statement | Sep 20, 2019 | — |
| S-1 | Registration statement | Sep 13, 2019 | — |
| 424B3 | Prospectus | Apr 26, 2019 | — |
| S-1 | Registration statement | Apr 17, 2019 | — |
| 424B5 | Prospectus supplement | Apr 1, 2019 | — |
| 424B4 | Prospectus | Aug 10, 2018 | — |
| S-1/A | Amended registration statement | Aug 6, 2018 | — |
| S-1 | Registration statement | Jul 27, 2018 | — |
| 424B3 | Prospectus | May 23, 2018 | — |
| 424B3 | Prospectus | Apr 27, 2018 | — |
| S-1 | Registration statement | Apr 20, 2018 | — |
| 424B3 | Prospectus | Apr 11, 2018 | — |
| 424B3 | Prospectus | Apr 11, 2018 | — |
| 424B5 | Prospectus supplement | Mar 29, 2018 | — |
| 424B3 | Prospectus | Feb 9, 2018 | — |
| 424B3 | Prospectus | Feb 9, 2018 | — |
| 424B3 | Prospectus | Feb 2, 2018 | — |
| 424B3 | Prospectus | Jan 30, 2018 | — |
| S-1/A | Amended registration statement | Jan 30, 2018 | — |
| S-1 | Registration statement | Jan 12, 2018 | — |
| POS AM | Post-effective amendment no. 1 to form s-1 | Jan 12, 2018 | — |
| 424B5 | Prospectus supplement | Dec 18, 2017 | — |
| S-3/A | Amendment no. 2 to form s-3 | Dec 13, 2017 | — |
| S-3/A | Registration statement | Nov 21, 2017 | — |
| S-3 | Shelf registration | Nov 9, 2017 | — |
| 424B4 | Prospectus | Aug 4, 2017 | — |
| S-1/A | Amended registration statement | Jul 28, 2017 | — |
| S-1/A | Amended registration statement | Jul 24, 2017 | — |
| S-1/A | Amended registration statement | Jul 13, 2017 | — |
| 424B3 | Prospectus | Jul 6, 2017 | — |
| S-1/A | Amended registration statement | Jul 3, 2017 | — |
| 424B3 | Prospectus | Jun 13, 2017 | — |
| 424B3 | Prospectus | Jun 12, 2017 | — |
| 424B3 | Prospectus | Jun 2, 2017 | — |
| 424B3 | Prospectus | Jun 2, 2017 | — |
| S-1 | Registration statement | May 12, 2017 | — |
| S-1/A | Amended registration statement | Apr 4, 2017 | — |
| S-1 | Registration statement | Feb 10, 2017 | — |
| 424B3 | Prospectus | Jan 22, 2016 | — |
| S-1/A | Amended registration statement | Jan 12, 2016 | — |
| S-1/A | Amended registration statement | Dec 29, 2015 | — |
| S-1/A | Amended registration statement | Nov 4, 2015 | — |
| S-1/A | Amended registration statement | Oct 16, 2015 | — |
| S-1 | Registration statement | Sep 11, 2015 | — |
| S-1/A | Amended registration statement | Jul 7, 2011 | — |
| S-1/A | Amended registration statement | Jun 23, 2011 | — |
| S-1/A | Amended registration statement | Jun 2, 2011 | — |
| S-1/A | Amended registration statement | May 9, 2011 | — |
| S-1/A | Amended registration statement | Apr 19, 2011 | — |
| S-1/A | Amended registration statement | Mar 16, 2011 | — |
| S-1/A | Amended registration statement | Jan 21, 2011 | — |
| S-1 | Registration statement | Nov 23, 2010 | — |
Showing 94 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CTXR (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- NV
- Headquarters
- Cranford, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1506251
- Former names
- Trail One, Inc. (until Sep 18, 2014); TrailOne, Inc. (until Jan 21, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.